Continuous Glucose Monitoring in Wound Care: Clinical Guide

Continuous Glucose Monitoring in Wound Care: Why It Changes Your Practice

Continuous glucose monitoring wound care integration is one of the most underutilized clinical tools in mobile and facility-based wound practice. If you treat patients with diabetic foot ulcers, venous leg ulcers complicated by diabetes, or pressure injuries in hyperglycemic patients, CGM data is now part of your clinical picture — whether or not you ordered the device.

Medicare expanded CGM coverage in 2023, removing the intensive insulin therapy requirement that once limited access to Type 2 patients on complex regimens. Today, a significant portion of your diabetic wound care patient population qualifies for and may already be using a CGM device. When your patient shows up wearing a Dexcom G7 or FreeStyle Libre sensor, that real-time glucose data belongs in your clinical assessment and your documentation. Here's how to use it — and how to document it — to support medical necessity, optimize healing expectations, and protect your claims from auditors.

How CGM Data Changes Your Wound Care Assessment

A single hemoglobin A1C value captures average glucose over 90 days. It tells you nothing about glucose variability — the daily pattern of highs and lows that determines the actual wound-healing environment at the tissue level. A patient with an A1C of 7.8% can look "controlled" on paper while spending more than a third of their day with glucose above 180 mg/dL, the threshold above which neutrophil function degrades, collagen synthesis slows, and infection risk climbs.

CGM devices record interstitial glucose every few minutes and generate actionable metrics that directly map to wound healing biology:

Time in Range (TIR): The percentage of time spent between 70–180 mg/dL. In diabetic wound care patients, TIR below 70% can be associated with prolonged healing trajectories and reduced response to advanced therapies.
Time Above Range (TAR): Time above 180 mg/dL. Sustained hyperglycemia impairs all three phases of wound healing — inflammatory, proliferative, and remodeling.
Glucose Management Indicator (GMI): An A1C estimate derived from CGM average glucose. A GMI that diverges significantly from the lab A1C often signals glycemic variability the A1C masked.
Coefficient of Variation (CV): A measure of glucose swings. High CV — typically above 36% — is associated with impaired tissue perfusion independent of average glucose level.

What to Review at the Visit

When a patient shares their CGM data at a wound care visit — via their smartphone app, a printed report, or a connected patient portal — focus your review on the 14-day summary. Look for TIR, average glucose, GMI, and any pattern of overnight hypoglycemia. Nocturnal hypoglycemic episodes can suppress growth hormone secretion during the hours when tissue repair is most active.

You don't need to interpret CGM data as an endocrinologist. You need to recognize when the glycemic environment is actively undermining what you're doing at the wound bed, document that finding, and act on it. That documentation is what separates a healable wound on paper from a billable one in a retrospective audit.

Documentation: Making CGM Data Work for Your Claims

Under Medicare's LCD requirements for wound care, claims for advanced wound care products and skin substitutes require evidence of a non-healing wound despite standard care and optimization of modifiable comorbidities. Poorly controlled diabetes is a documented comorbidity that impairs healing — and CGM data is the most precise tool available in 2026 for characterizing that comorbidity.

Here's how to document CGM findings in your wound care visit note:

When the patient reports CGM data verbally: "Patient reports CGM data showing estimated time-in-range approximately 45% over the past 14 days, with frequent excursions above 250 mg/dL. Suboptimal glycemic control documented as contributing factor to non-healing. Patient counseled on relationship between glucose variability and wound healing. Referral placed to primary care physician for medication reassessment."

When you can access the CGM report directly: "Review of patient's CGM data (14-day period ending [date]) shows: TIR 52%, GMI 8.2%, average glucose 193 mg/dL. Glycemic variability with significant hyperglycemia documented as active barrier to wound healing. Clinical response: endocrinology referral placed; patient education provided."

The critical element is the documented clinical response. Noting a CGM metric without acting on it provides incomplete medical necessity support. Auditors reviewing a claim for a wound that hasn't met the four-week improvement standard will look for evidence that you identified — and addressed — modifiable barriers to healing. CGM-documented glycemic dysregulation, paired with a referral or treatment plan modification, is precisely that evidence.

For more on documenting diabetic foot ulcers for Medicare, including the comorbidity documentation requirements that underpin skin substitute eligibility, see the linked guide.

CGM Integration in Your Mobile Wound Care Workflow

Incorporating CGM data review into a mobile or SNF-based wound care practice requires minimal workflow change. The upside — stronger documentation, better clinical decisions, fewer non-healing wound dead ends — is disproportionate to the effort.

At intake: Add a single question to your patient intake process: "Do you use a continuous glucose monitor?" and "Can you share your CGM report at your visit?" Most CGM apps generate a shareable PDF report within seconds. Patients using Dexcom Clarity or LibreView can email it to your practice before the visit.

In your visit note template: Add a CGM data section with three structured fields: device type, 14-day summary metrics (TIR, average glucose, GMI), and clinical action taken. A structured field takes less time to complete than a narrative and makes the data easier to locate in a post-payment audit.

When the patient doesn't have a CGM: If your diabetic foot ulcer patient isn't using CGM and their wound is stalling despite appropriate local care, document a recommendation to the prescribing provider. A non-healing wound in a patient with uncharacterized glycemic variability is one of the strongest clinical arguments for initiating CGM. Your documented recommendation becomes part of the care coordination record.

EMR integration: Several wound care EMR platforms now support direct integration with CGM data streams through Apple Health, Dexcom Clarity API, or LibreView. If your current EMR doesn't offer this, it's worth adding to your next vendor review checklist. The practices that integrate CGM data routinely will have a documentation advantage in audits compared to those relying on quarterly A1C values alone.

Medicare Coverage for CGM: What Your Patients Can Access

Prior to 2023, Medicare CGM coverage was restricted to patients using intensive insulin regimens — multiple daily injections or an insulin pump. That requirement has been eliminated. Today, Medicare covers CGM for beneficiaries who:

Have diabetes (Type 1 or Type 2)
Are being treated by a physician or qualified non-physician practitioner for diabetes
Require frequent glucose monitoring as part of their diabetes management plan

This expanded access means many of your diabetic wound care patients now qualify for a CGM device if they don't already have one. CGM supplies are covered under the Medicare Diabetes Supply benefit — billed by a DME supplier, not by wound care providers. You are not billing for CGM. You are incorporating the data it generates into your clinical assessment and documentation, which is within your scope and directly strengthens your wound care claims.

If a patient doesn't have CGM and could benefit, document a referral or recommendation in your note. You're not responsible for initiating the device — but you can establish the clinical case for it and coordinate with the prescribing provider.

Key Takeaways

CGM reveals what A1C conceals: Time in Range, glucose variability, and hyperglycemic burden give a more accurate picture of the wound-healing environment than a quarterly A1C draw, and belong in your clinical documentation.
Document CGM findings with a clinical action: Recording a metric without responding to it provides incomplete medical necessity support. Note the finding, explain its clinical significance, and document what you did about it.
Medicare CGM coverage is now broad: The 2023 expansion removed the intensive insulin therapy requirement, so a larger portion of your diabetic wound care patients qualifies for or already uses CGM — assess at every visit.
Integration is low-effort and high-return: A single intake question, a structured note field, and a referral protocol can capture CGM data for most patients without adding meaningful visit time.
CGM documentation strengthens non-healing wound justifications: When a wound isn't responding to standard care, documented glycemic dysregulation explains the clinical trajectory and protects claims from audit scrutiny under LCD requirements.